CN1123141A - Aerosol preparation and preparation method thereof - Google Patents
Aerosol preparation and preparation method thereof Download PDFInfo
- Publication number
- CN1123141A CN1123141A CN 94110548 CN94110548A CN1123141A CN 1123141 A CN1123141 A CN 1123141A CN 94110548 CN94110548 CN 94110548 CN 94110548 A CN94110548 A CN 94110548A CN 1123141 A CN1123141 A CN 1123141A
- Authority
- CN
- China
- Prior art keywords
- sulfate
- distilled water
- glycerol
- composition
- weight percentage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The preparation for curing respiratory tract infection comprises antibiotic, solvant, aids, seasoning and nubulizing agent. Gentamicin sulfate, kanamycin sulfate, ribostamycin sulfate and sisomicin sulfate can be used as antibiotic medcine; distilled water can be used as solvent; glycol, glycerine, ethyl alcohol, dimethy sulfoxide and span 85 can be used as aids; borneol, peppermint oil and other perfume can be used as seasoning. Advantage: convenient medicine application, less toxic side effect and high curative rate.
Description
The invention provides a kind of medicinal aerosol formulations and compound method thereof.
Its curative effect of the application of antibiotic medicine depends on the drug level of infection site to a great extent, and the concentration of infection site antibacterials is principal elements of decision clinical efficacy.Think that in theory " target position " administration can improve medicine to predetermined localized selectivity of focus of human body and accuracy, make the drug effect optimization and the whole body toxic and side effects is reduced to minimum degree.
At present, clinically treatment of diseases such as tonsillitis, pharyngitis, laryngitis, acute and chronic tracheitis, bronchitis are extensively adopted antibiotics such as gentamycin, kanamycin, medication mainly is intramuscular injection, and other has the Therapeutic Method of atomizing " target position " administration.But medication mainly sprays into, sucks with aerosol apparatus, high pressure oxygen, high-pressure pump and ultrasonic atomizatio.Its employed medicinal liquid is generally prepared by the medical worker temporarily.The patient need arrive hospital and can receive treatment.
It is considered herein that: the intramuscular injection whole body administration that as above " target position " route of administration of treatment respiratory tract infection compares is more excellent, and this method can improve the availability of medicine, owing to medicine has reduced its toxic and side effects without systemic circulation.But present medication falls behind, and the patient need run hospital and can receive treatment under medical personnel's help.This had both increased medical personnel's labor intensity, had wasted patient or patient monitoring person's time again.
The present invention is a purpose with toxic and side effects and the convenient popular Heal Thyself that improves drug utilization degree, reduction medicine, and a kind of antibiotics aerosol preparations and compound method are provided.
Preparation of the present invention, be after to the physicochemical characteristics of each antibiotics, biological nature comparative study, preferred chemical property is stable, the aminoglycosides antibiotics that does not have irritated reaction and have a bactericidal action is a principal agent, and this class antibiotic comprises kanamycin, gentamycin, micronomicin, ribostamycin, Sissomicin and amikacin, tobramycin, dibekacin, isepamicin etc.
The used propellant of the present invention is dichlorodifluoromethane (F
12), also can be other any hydrogen fluorocarbon or hydrochlorofluorocarsolvent or its mixture that have enough vapour pressures at normal temperatures, suitably preferred propellant comprises: C
1-4Hydrochlorofluorocarsolvent: CFCl
3, CF
2ClCF
2Cl, CH
2ClF, CClF
2CHClF, CF
3CHClF, CHF
2CClF
2, CHClFCHF
2, CF
3CHCl and CClF
2CH
3C
1-4The hydrogen-containing carbon fluorine compounds, for example: CHF
2CHF
2, CF
3CH
2F, CHF
2CH
3And CF
3CF
2CF
3And perfluorocarbon, for example: CF
3CF
3And CF
3CF
2CF
3
This professional field technical staff can find out at an easy rate, adopts above-claimed cpd to make propellant, can be the mixture of unification compound or itself and other above-claimed cpd.
The solvent of preparation principal agent of the present invention is a distilled water, can contain other adjuvant in addition.Comprise various suitable flavoring agents.For example: the spice of surfactant (Tween 80, sorbester p37 etc.), dimethyl sulfoxide, ethanol, ethylene glycol, glycerol and different flavor etc.
The compound method of aerosol preparations of the present invention is antimicrobial drug, solvent, auxiliary agent, flavoring agent and propellant to be packed in proportion be with in the container of valve.It is principal agent that antimicrobial drug adopts gentamycin sulfate, kanamycin sulfate, Micronomicin Sulfate, Vistamycin, Baymicin and other antibiotics, with the distilled water is solvent, with glycerol, ethylene glycol, ethanol, dimethyl sulfoxide and Arlacel-85 etc. is auxiliary agent, with Borneolum Syntheticum, Herba Menthae wet goods is flavoring agent, is propellant with F12.Its cooperation ratio is: 0.5-20:5-95:1-50:0.001-1.5:2.5-50.
Preparation of the present invention can be loaded in the container that can bear used propellant vapour pressure.This container seals if then use metering valve above 5ml.
The present invention's goods leave standstill the back and form three-phase: gas phase, water and propellant are mutually.After shaking stirring, can obtain having fabulous suspension for property of medicine energy.
Preparation of the present invention is fit to gentle or the serious acute and chronic respiratory tract infection of treatment.As: tonsillitis, diseases such as rhinitis, pharyngitis, laryngitis, tracheobronchitis.Preparation of the present invention also can be used for prophylactic treatment.In addition, preparation of the present invention also can be used for skin burn, scald and trauma infection contamination.As for dosage and frequency, will depend on patient's the state of an illness and the age.This can be by the clinicist according to the clinical symptoms final decision.
Preparation of the present invention is with single-dose thing and propellant F such as gentamycins
12For example illustrates its implementation method.Certainly, can be that the mixture of any of above-mentioned principal agent or itself and other said medicine also can add other adequate stability in addition good and do not have anaphylactoid other antimicrobial drugs or Chinese herbal medicine is made compound preparation for principal agent.
Embodiment prescription weight of material percentage ratio (%) (1) gentamycin sulfate 0.5-16 ethylene glycol 5-95 F
122.5-40 (2) gentamycin sulfate 0.5-16 ethanol 5-50 distilled water 10-95 Oleum menthae 0.001-0.1 F
122.5-40 (3) gentamycin sulfate 0.5-16 glycerol 5-45 distilled water 5-40 F
125-40 (4) gentamycin sulfate 0.5-16 ethanol 5-30 glycerol 5-40 Arlacel-85 0.1-5 F
122.5-50 (5) kanamycin sulfate 0.5-16 glycerol 5-40 distilled water 10-90 Oleum menthae 0.005-0.01 F
125-40 (6) kanamycin sulfate 0.5-16 distilled water 5-95 ethanol 5-20 glycerol 5-50 F
125-50 (7) Micronomicin Sulfate 0.5-16 glycerol 1-40 distilled water 5-90 F
125-45 (8) Vistamycin 0.5-16 glycerol 5-50 distilled water 5-45 F
122.5-50 (9) sisomicin sulfate 0.5-16 glycerol 0-50 distilled water 5-90 Borneolum Syntheticum 1-1.5 F
122.5-50
The preparation method of preparation of the present invention is: dissolving mixings such as principal agent and solvent, adjuvant are made into concentrated solution earlier.Concentrated solution is sub-packed in after aseptic process in the suitable pressure vessel (aluminium pot or slush moulding vial).Behind the packaged quantitative valve body, charge into a certain amount of propellant promptly by valve body.
Claims (10)
1, a kind of aerosol preparations and compound method thereof, comprise compositions such as antibiotics, solvent, auxiliary agent, flavoring agent and propellant, it is characterized in that antibiotics is gentamycin sulfate, kanamycin sulfate, Micronomicin Sulfate, Vistamycin, Sissomicin etc.; Solvent is a distilled water; Auxiliary agent is glycerol, ethylene glycol, ethanol, dimethyl sulfoxide and Arlacel-85 etc.; Flavoring agent is Borneolum Syntheticum, Oleum menthae and other spices and essences; Propellant is fluorocarbon F
12The weight percentage of each composition is antibiotics 0.5-20, and solvent 5-25, auxiliary agent are 1-50, and flavoring agent 0.001-1.5, propellant are 2.5-45.
2, method according to claim 1, the weight percentage that it is characterized in that each composition is gentamycin sulfate 0.5-16, ethylene glycol 5-95, F
125-40.
3, method according to claim 1, the weight percentage that it is characterized in that each composition is gentamycin sulfate 0.5-16, ethanol 10-45, distilled water 5-40, Oleum menthae 0.001-0.1, F
125-40.
4, method according to claim 1, the weight percentage that it is characterized in that each composition is gentamycin sulfate 0.5-16, glycerol 5-45, distilled water 5-50, F
125-40.
5, method according to claim 1, the weight percentage that it is characterized in that each composition is gentamycin sulfate 0.5-16, ethanol 5-30, glycerol 5-40, Arlacel-85 0.1-5, F
125-50.
6, method according to claim 1, the weight percentage that it is characterized in that each composition is kanamycin sulfate 0.5-20, glycerol 5-40, distilled water 10-90, Oleum menthae 0.005-0.01, F
125-40.
7, method according to claim 1, the weight percentage that it is characterized in that each composition is kanamycin sulfate 0.5-16, glycerol 5-50, ethanol 5-20, distilled water 5-45, F
125-50.
8, method according to claim 1, the weight percentage that it is characterized in that each composition is Micronomicin Sulfate 0.5-16, glycerol 5-40, distilled water 5-95, F
125-45.
9, method according to claim 1, the weight percentage that it is characterized in that each composition is sisomicin sulfate 0.5-16, glycerol 5-40, distilled water 5-45, F
122.5-50, Borneolum Syntheticum 1.5.
10, method according to claim 1, the weight percentage that it is characterized in that each composition is Vistamycin 0.5-16, glycerol 1-50, distilled water 5-45, F
122.5-50.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN94110548A CN1069192C (en) | 1994-04-21 | 1994-04-21 | Aerosol preparation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN94110548A CN1069192C (en) | 1994-04-21 | 1994-04-21 | Aerosol preparation and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1123141A true CN1123141A (en) | 1996-05-29 |
| CN1069192C CN1069192C (en) | 2001-08-08 |
Family
ID=5034505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN94110548A Expired - Fee Related CN1069192C (en) | 1994-04-21 | 1994-04-21 | Aerosol preparation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1069192C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100337614C (en) * | 1998-09-22 | 2007-09-19 | 气体药品技术公司 | Medicinal aerosol formulation |
| CN102724973A (en) * | 2009-10-30 | 2012-10-10 | 生物基因创新有限责任公司 | Methylsulfonylmethane (MSM) for treatment of drug resistant microorganisms |
| US8546373B2 (en) | 2009-10-30 | 2013-10-01 | Biogenic Innovations, Llc | Methods of sensitizing drug resistant microorganisms using methylsulfonylmethane (MSM) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62273912A (en) * | 1986-05-21 | 1987-11-28 | Kao Corp | Aerosol agent to be applied to human body |
| JPH01283225A (en) * | 1988-05-10 | 1989-11-14 | Toyo Jozo Co Ltd | Aerosol preparation for treating infectious disease of bovine respiratory organ and treating method using the same |
-
1994
- 1994-04-21 CN CN94110548A patent/CN1069192C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100337614C (en) * | 1998-09-22 | 2007-09-19 | 气体药品技术公司 | Medicinal aerosol formulation |
| CN102724973A (en) * | 2009-10-30 | 2012-10-10 | 生物基因创新有限责任公司 | Methylsulfonylmethane (MSM) for treatment of drug resistant microorganisms |
| US8546373B2 (en) | 2009-10-30 | 2013-10-01 | Biogenic Innovations, Llc | Methods of sensitizing drug resistant microorganisms using methylsulfonylmethane (MSM) |
| CN102724973B (en) * | 2009-10-30 | 2014-08-27 | 生物基因创新有限责任公司 | Methylsulfonylmethane (MSM) for treatment of drug resistant microorganisms |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1069192C (en) | 2001-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101141220B1 (en) | Foamable pharmaceutical compositions and methods for treating a disorder | |
| EP0510561B1 (en) | Oral, cutaneous and intravaginal pharmaceutical compositions in the form of foam | |
| US5733569A (en) | Galenic compositions comprising calcitonin and their use | |
| CN101663022A (en) | topical pharmaceutical formulation | |
| ES2834985T3 (en) | Composition containing cineole for nasal administration | |
| KR20200050941A (en) | Treatment of skin disorders | |
| JP7286117B2 (en) | Compositions for the manufacture of products for public health | |
| WO2004067012A1 (en) | Limposomes containing asiaticoside and the uses thereof | |
| CN1123141A (en) | Aerosol preparation and preparation method thereof | |
| US11951077B2 (en) | Stabilized menthol and other volatile compound compositions and methods | |
| US6355251B1 (en) | Compositions and methods for epidermal chemexfoliation | |
| NZ537186A (en) | Nasal compositions comprising a mucopolysaccharide and propylene glycol | |
| CN110755573B (en) | A refreshing solution for inhalation and its preparation method | |
| JP4450545B2 (en) | Aerosol formulation | |
| JP2018021027A (en) | Pharmaceutical preparation containing loxoprofen | |
| CN1209320A (en) | Medicine | |
| JPH0366618A (en) | Pharmaceutical compound | |
| WO2009070829A1 (en) | Non-aqueous oil-based fentanyl compositions for transmucosal administration | |
| US6410034B1 (en) | Dermal absorption-promoting agent | |
| JPH0354647B2 (en) | ||
| JPS6339822A (en) | Transnasal calcitonin agent | |
| WO2010094218A1 (en) | Oral spray or aerosol of palonosetron | |
| FR2467601A3 (en) | Antiinflammatory compsns. for external use - contg. vegetable extracts and a fluorocarbon propellant and refrigerant | |
| JP2004075571A (en) | Nasal drop and method for producing the same | |
| WO2021214789A1 (en) | Novel uses of apremilast |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |